Advertisement

Endocrine

, Volume 43, Issue 1, pp 112–119 | Cite as

Metabolic syndrome between two ethnic minority groups (Circassians and Chechens) and the original inhabitants of Jordan

  • Rana Dajani
  • Yousef S. Khader
  • Nancy Hakooz
  • Raja Fatahalla
  • Farouk Quadan
Original Article

Abstract

The prevalence of metabolic syndrome is increasing worldwide and exhibits variation among ethnic groups. The objective of this study was to estimate and compare the prevalence of metabolic syndrome and its components between two ethnic groups (Circassians and Chechens) in Jordan and the original inhabitants of Jordan. Data were collected from a cross-sectional study of Circassian (n = 436), Chechen (n = 355), and Jordanian (n = 3234) population aged 18 years and older. Metabolic syndrome was defined according to International Diabetes Federation criteria. Age-standardized prevalence rate of metabolic syndrome was Jordanians 38.0 %, Circassians 32.0 %, and Chechens 33.7 %. Compared to Jordanians, both minority groups had lower means of body mass index, total cholesterol, fasting blood glucose, and triglycerides. The means of high-density lipoprotein and low-density lipoprotein were significantly higher among Circassians compared to Jordanians and Chechens. The odds of BMI defined by overweight and obesity and diabetes were less common among Circassians and Chechens compared to Jordanians. The prevalence of the metabolic syndrome and its individual components is relatively high in the three ethnic groups compared to world. Variation in components between groups may relate to ethnicity. Therefore, a community-based integrated approach is needed that would include behavioral, social changes that would lead to the prevention and treatment of the metabolic syndrome.

Keywords

Metabolic syndrome Epidemiology Ethnic Jordan Circassians Chechens 

Abbreviations

CVD

Cardiovascular disease

DBP

Diastolic blood pressure

LDL

Low-density lipoprotein

HDL

High-density lipoprotein

MeS

Metobolic syndrome

SBP

Systolic blood pressure

Notes

Acknowledgments

This study has been funded by the Higher Council of Science and Technology, Jordan. We would like to thank the Circassian and Chechan communities for their participation in this study.

Conflict of interest

The authors declare that there are no competing financial interests associated with this manuscript.

References

  1. 1.
    WHO, W.H.O.: Core Health Indicators. World Health Statistics In. (2006)Google Scholar
  2. 2.
    Ministry of Health, T.H.K.o.J., Mortality in Jordan (Ministry of Health, The Hashemite Kingdom of Jordan, Amman, 2008)Google Scholar
  3. 3.
    K. Ajlouni, Y.S. Khader, A. Batieha, H. Ajlouni, M. El-Khateeb, An increase in prevalence of diabetes mellitus in Jordan over 10 years. J. Diabetes Complicat. 22(5), 317–324 (2008)PubMedCrossRefGoogle Scholar
  4. 4.
    Y. Khader, A. Batieha, H. Ajlouni, M. El-Khateeb, K. Ajlouni, Obesity in Jordan: prevalence, associated factors, comorbidities, and change in prevalence over ten years. Metab. Syndr. Relat. Disord. 6(2), 113–120 (2008)PubMedCrossRefGoogle Scholar
  5. 5.
    F.M. Mubarak, E.S. Froelicher, H.Y. Jaddou, K.M. Ajlouni, Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann. Saudi Med. 28(5), 346–351 (2008)PubMedCrossRefGoogle Scholar
  6. 6.
    Y.S. Khader, A. Batieha, M. El-Khateeb, M. Al Omari, K. Ajlouni, Prevalence of dyslipidemia and its associated factors among Jordanian adults. J. Clin. Lipidol. 4(1), 53–58 (2010)PubMedCrossRefGoogle Scholar
  7. 7.
    Y. Khader, A. Bateiha, M. El-Khateeb, A. Al-Shaikh, K. Ajlouni, High prevalence of the metabolic syndrome among Northern Jordanians. J. Diabetes Complicat. 21(4), 214–219 (2007)PubMedCrossRefGoogle Scholar
  8. 8.
    K. Shishani, R. Dajani, Y. Khader, Hypertension risk assessment in the largest ethnic groups in Jordan. J. Immigrant Minority Health (2011). doi: 10.1007/s10903-011-9533-y
  9. 9.
    G. Barbujani, I.S. Nasidze, G.N. Whitehead, Genetic diversity in the Caucasus. Hum. Biol. 66(4), 639–668 (1994)PubMedGoogle Scholar
  10. 10.
    W. Richmond, The Northwest Caucasus: Past, Present, Future, vol. 12. Central Asian Studies Series Routledge (Routledge Press, Routledge, 2008)Google Scholar
  11. 11.
    K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith Jr, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2009)PubMedCrossRefGoogle Scholar
  12. 12.
    Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, S.B. Heymsfield, The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 163(4), 427–436 (2003)PubMedCrossRefGoogle Scholar
  13. 13.
    L.A. Jaber, M.B. Brown, A. Hammad, Q. Zhu, W.H. Herman, The prevalence of the metabolic syndrome among Arab Americans. Diabetes Care 27(1), 234–238 (2004)PubMedCrossRefGoogle Scholar
  14. 14.
    H.F. Abdul-Rahim, A. Husseini, E. Bjertness, R. Giacaman, N.H. Gordon, J. Jervell, The metabolic syndrome in the West Bank population: an urban-rural comparison. Diabetes Care 24(2), 275–279 (2001)PubMedCrossRefGoogle Scholar
  15. 15.
    J.A. Al-Lawati, A.J. Mohammed, H.Q. Al-Hinai, P. Jousilahti, Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 26(6), 1781–1785 (2003)PubMedCrossRefGoogle Scholar
  16. 16.
    A.K. Ozsahin, A. Gokcel, N. Sezgin, M. Akbaba, N. Guvener, L. Ozisik, B.M. Karademir, Prevalence of the metabolic syndrome in a Turkish adult population. Diabetes Nutr. Metab. 17(4), 230–234 (2004)PubMedGoogle Scholar
  17. 17.
    F. Azizi, P. Salehi, A. Etemadi, S. Zahedi-Asl, Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res. Clin. Pract. 61(1), 29–37 (2003)PubMedCrossRefGoogle Scholar
  18. 18.
    A. Ramachandran, C. Snehalatha, K. Satyavani, S. Sivasankari, V. Vijay, Metabolic syndrome in urban Asian Indian adults—a population study using modified ATP III criteria. Diabetes Res. Clin. Pract. 60(3), 199–204 (2003)PubMedCrossRefGoogle Scholar
  19. 19.
    D.B. Carr, K.M. Utzschneider, R.L. Hull, K. Kodama, B.M. Retzlaff, J.D. Brunzell, J.B. Shofer, B.E. Fish, R.H. Knopp, S.E. Kahn, Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53(8), 2087–2094 (2004)PubMedCrossRefGoogle Scholar
  20. 20.
    C.H. Tsai, T.C. Li, C.C. Lin, H.S. Tsay, Factor analysis of modifiable cardiovascular risk factors and prevalence of metabolic syndrome in adult Taiwanese. Endocrine 40(2), 256–264 (2011)PubMedCrossRefGoogle Scholar
  21. 21.
    A. Esteghamati, A. Zandieh, O. Khalilzadeh, A. Morteza, A. Meysamie, M. Nakhjavani, M.M. Gouya, Clustering of leptin and physical activity with components of metabolic syndrome in Iranian population: an exploratory factor analysis. Endocrine 38(2), 206–213 (2010)PubMedCrossRefGoogle Scholar
  22. 22.
    S. Taslim, E.S. Tai, The relevance of the metabolic syndrome. Ann. Acad. Med. Singapore 38(1), 29–30 (2009)PubMedGoogle Scholar
  23. 23.
    H.N. Ginsberg, P.R. MacCallum, The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr. 4(2), 113–119 (2009)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Rana Dajani
    • 1
  • Yousef S. Khader
    • 2
  • Nancy Hakooz
    • 3
  • Raja Fatahalla
    • 1
  • Farouk Quadan
    • 1
  1. 1.Department of Biology and BiotechnologyHashemite UniversityZarqaJordan
  2. 2.Department of Community Medicine, Public Health and Family Medicine, Faculty of MedicineJordan University for Science and TechnologyIrbidJordan
  3. 3.Department of Biopharmaceutics and Clinical Pharmacy, Faculty of PharmacyUniversity of JordanAmmanJordan

Personalised recommendations